Open AccessReview: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer
Author(s) -
Tanya B. Dorff,
Cathy Tangen,
E. David Crawford,
Daniel P. Petrylak,
Celestia S. Higano,
Derek Raghavan,
David I. Quinn,
Nicholas J. Vogelzang,
Ian M. Thompson
Publication year - 2009
Publication title -
therapeutic advances in medical oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 49
eISSN - 1758-8359
pISSN - 1758-8340
DOI - 10.1177/1758834009343454
Subject(s) - medicine , prostate cancer , oncology , docetaxel , clinical trial , chemotherapy , androgen deprivation therapy , cancer
The major goals of the SWOG-GU committee in the area of advanced prostate cancer are to improve the survival and quality of life of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom